Anthrax

Specialty pharmaceutical company Emergent BioSolutions has initiated a non-interference Phase II study of BioThrax (anthrax vaccine adsorbed) to treat exposure to anthrax spores.

The randomised study will assess non-interference of BioThrax when administed with antibiotics, and is designed to support a new indication application for the vaccine to treat post-exposure prophylaxis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BioThrax is currently the only FDA-licensed vaccine indicated for pre-exposure prophylaxis.

Emergent BioSolutions biodefense division EVP and president Adam Havey said the BioThrax post-exposure prophylaxis programme is being advanced by the company to improve the clinical utility of the vaccine.

"Inhalation anthrax is highly lethal when left untreated. Through our partnership with the Biomedical Advanced Research and Development Authority (BARDA), we are exploring how our vaccine can fit in the current PEP treatment regimen, which consists of only oral antibiotics," Havey said.

See Also:

"We remain committed to working in partnership with BARDA to advance critical countermeasures that help ensure the nation’s preparedness."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Assessment of the vaccine’s impact on ciprofloxacin when the antibiotic is administered before and after a 3-dose series of BioThrax is the primary objective of the non-interference study.

The open-label study, which will enrol a total of 120 healthy adult volunteers, is also designed to provide additional safety data on the simultaneous administration of ciprofloxacin and BioThrax.

Company expects to report preliminary study data in the fourth quarter of 2013.

Image: A photomicrograph of Bacillus anthracis bacteria using Gram-stain technique. Photo: Courtesy of CDC.